The study's authors reviewed CCTA imaging results taken before and after radiotherapy, evaluating each image for signs of coronary calcification and inflammation.
Patient outcomes do not appear to be negatively impacted by these risks, researchers noted. The new data were presented at Heart Rhythm 2025 and published in JACC: Clinical Electrophysiology.
COVID-19 may help explain the increased rates of cardiac and noncardiac mortality among TAVR patients, but there are several other factors to consider as well. Researchers explored nearly 11 years of STS/ACC registry data to learn more.
Researchers detailed their experience performing the very first TAVR procedures with the Venus-PowerX TAVR valve from Venus MedTech. The valve includes a wire-controlled mechanism that makes it possible to recapture after full deployment.
Sending helpful alerts through email and the electronic health record can make a significant impact on patient care, according to new data presented at ACC.25 and published in Circulation.
Care teams throughout the U.S. and U.K. are now exploring the safety and effectiveness of using Shockwave Medical's new Javelin IVL catheters to treat challenging, difficult-to-cross coronary lesions.
The late-breaking five-year results of the Evolut Low-Risk Trial presented at the American College of Cardiology (ACC) 2025 meeting in late March, showed positive results for the Evolut transcatheter aortic valve replacement (TAVR) system vs. surgical aortic valve replacement (SAVR).
Radiology practices are already operating on razor thin margins, with price increases prompting calls for congressional action to prevent further damage.
